Similarly, there were no clear patterns across clinical and endoscopic outcomes with risankizumab maintenance therapy across AT-IR subgroups by mechanism of action (TNF inhibitor, vedolizumab, JAK inhibitor) or specific TNF inhibitor type (infliximab, adalimumab, golimumab); these subgroups were not mutually exclusive (Figures 2 and S3). The gene discussed is TNF; the disease is ataxia telangiectasia.